Skip to main content
Fig. 5 | Cancer Nanotechnology

Fig. 5

From: Delivery of CXCL9/10/11 plasmid DNAs promotes the tumor-infiltration of T cells and synergizes with PD1 antibody for treating lung cancer

Fig. 5

Anti-PD1 antibody significantly enhances the anti-tumor efficacy of NPpCXCL9/10/11 of the LLC model. A PD1 expression of CD8 + T cells was examined by flow cytometry. B PD1 expression in tumor tissues was examined by western blot. C Tumor growth curve. Mice bearing LLC tumors were treated with aPD1, NPpCXCL9/10/11, or the combination. The equivalent injection dose of pCXCL9, pCXCL10, and pCXCL11 was 15 μg per mice, and the injection dose of aPD1 was 100 μg per mice. Data represent means ± SD. n = 10 mice, **p < 0.01, ***p < 0.001. D Survival curve of mice bearing LLC tumors

Back to article page